Cipla Ltd
CIPLABSE 500087PharmaceuticalsMkt cap ₹1,08,808 Cr
Whole group, including subsidiaries — the figures companies headline.
Revenue · Q1 FY27
₹7,119 Cr
YoY +2.3%QoQ +8.8%
Net profit · Q1 FY27
₹786 Cr
YoY -39.2%QoQ +44.8%
Net margin · Q1 FY27
11.0%
-7.5 pts vs Q1 FY26
Net profit · FY26
₹3,862 Cr
YoY -26.7%
Quarterly results
| ₹ Cr | Q1 FY27 Apr–Jun 2026 | Q4 FY26 Jan–Mar 2026 | Q3 FY26 Oct–Dec 2025 | Q2 FY26 Jul–Sep 2025 | Q1 FY26 Apr–Jun 2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | 7,119 | 6,541 | 7,074 | 7,589 | 6,957 | +2.3% |
| Other income | 211 | 148 | 206 | 269 | 259 | -18.4% |
| Total income | 7,330 | 6,689 | 7,281 | 7,858 | 7,216 | +1.6% |
| Profit before tax | 1,082 | 707 | 893 | 1,854 | 1,770 | -38.9% |
| Tax | 295 | 157 | 219 | 500 | 478 | -38.3% |
| Net profit | 786 | 543 | 674 | 1,353 | 1,292 | -39.2% |
| Net margin | 11.0% | 8.3% | 9.5% | 17.8% | 18.6% |
Annual results
| ₹ Cr | FY26 Apr 2025–Mar 2026 | FY25 Apr 2024–Mar 2025 | FY24 Apr 2023–Mar 2024 | FY23 Apr 2022–Mar 2023 | FY22 Apr 2021–Mar 2022 | YoY |
|---|---|---|---|---|---|---|
| Revenue | 28,163 | 27,548 | 25,774 | 22,753 | 21,763 | +2.2% |
| Other income | 882 | 862 | 747 | 475 | 281 | +2.3% |
| Total income | 29,045 | 28,409 | 26,521 | 23,229 | 22,044 | +2.2% |
| Profit before tax | 5,224 | 6,821 | 5,702 | 4,038 | 3,493 | -23.4% |
| Tax | 1,354 | 1,530 | 1,547 | 1,203 | 934 | -11.5% |
| Net profit | 3,862 | 5,269 | 4,154 | 2,833 | 2,547 | -26.7% |
| Net margin | 13.7% | 19.1% | 16.1% | 12.4% | 11.7% |
BIC's take
We haven't covered Cipla Ltd yet. Browse our sector reports →
Source: BSE filings · Data as of 2 Oct 2026, 6:54 pm IST· ₹ crore unless stated. Covers BSE 500 companies only. Consolidated figures include subsidiaries; standalone is the parent company alone. Growth is shown only against a positive base. Not investment advice — check the company's full filing before acting.